纳美芬对患者麻醉恢复质量的有效性:多中心随机对照试验研究方案
本研究为前瞻性、安慰剂对照、两组平行、多中心、双盲、随机临床试验,计划纳入520例患者,比较手术结束时单次给予纳美芬0.25 µg/kg与等体积0.9%氯化钠溶液对全麻后恢复质量的影响。主要结局为麻醉结束至麻醉后监护室Aldrete恢复评分≥9的时间间隔,并评估拔管时间、RASS评分、MoCA定向评分≥5的时间、VAS评分及不良反应。
要点
- 纳美芬0.25 µg/kg组与0.9%氯化钠溶液组各随机分配,主要观察Aldrete评分≥9的恢复时间。
- 次要指标包括拔管时间、拔管时RASS评分、MoCA定向评分≥5时间、VAS评分及PONV和瘙痒。
- 该试验旨在为优化全麻后恢复质量提供临床证据。
核心结论
- 该试验旨在研究小剂量纳美芬能否缩短手术结束至Aldrete评分≥9的时间并改善阿片类药物引起的不良反应。
研究设计与样本
- 前瞻性、安慰剂对照、两组平行、多中心、双盲、随机临床试验,计划纳入520例患者。
- 干预组手术结束时单次给予纳美芬0.25 µg/kg,对照组给予等体积0.9%氯化钠溶液。
主要发现
- 主要结局为麻醉结束至麻醉后监护室Aldrete恢复评分≥9的时间间隔。
- 其他变量包括手术结束至拔管时间、拔管时RASS评分、MoCA定向评分≥5的时间、VAS评分及麻醉后监护室和术后24小时PONV与瘙痒等不良反应。
关键数值与推荐
- 纳美芬剂量为0.25 µg/kg,手术结束时单次给药。
- 主要恢复终点为Aldrete恢复评分≥9。
- MoCA定向评分恢复终点为≥5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: So far, the recovery quality after general anesthesia is still unsatisfied. Nalmefene is a drug to treat opioid overdose and reverse opioid actions. We aim to investigate the efficacy of nalmefene on optimizing the recovery quality of patients after general anesthesia. METHODS: It is a prospective, placebo-controlled, two-arm parallel groups, multicentre, double-blind, randomized (PPPMDR) clinical trial. The participants (n = 520) will be randomly assigned into two groups. Each patient will receive either: a single dose of nalmefene 0.25 µg/kg in the intervention group, or the same volume of 0.9% NaCl solution in the control group at the end of the surgery. The primary outcome will be the time interval between the end of anaesthesia and recovery endpoints achieved (Aldrete recovery score ≥ 9) in post-anesthesia care unit (PACU). The other variables are the time interval from the end of operation to extubation; Richmond Agitation Sedation Scale (RASS) score at extubation; the time at Montreal Cognitive Assessment Scale (MoCA) orientation score ≥ 5; visual analog scale (VAS) score and adverse effects including postoperative nausea and vomiting (PONV), and pruritus in PACU and 24 h postoperatively. ANALYSIS: This trial aims to study whether small dose of nalmefene can shorten the time from the end of surgery to Aldrete score ≥ 9 and improve opioid-induced side effects.This trial focuses on providing the reliable clinical evidence for satisfactory quality of recovery. ETHICS AND DISSEMINATION: This clinical trial has been approved and supported by the ethics committee of the Renji Hospital, Shanghai Jiaotong University, School of Medicine (KY2020-150); Shanghai Tongren Hospital (2021-030-01);The First Affiliated Hospital of Guangxi Medical University (2021-032); and The First Affiliated Hospital of Zhengzhou University(2021-KY-0495-003). Analysis of the study results will be submitted to a peer-reviewed journal for publication. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04713358, Registered on September 23, 2021.
引用
- Ma X, Liu J, Tang Y, et al. The efficacy of nalmefene on anesthetic recovery of patients: a study protocol for a multicenter randomized controlled trial. Trials. 2023. PMID: 36859316. doi:10.1186/s13063-023-07169-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。